Traditional weight loss drugs often limit their application due to systemic side effects
Note: For complete details, please review product monographs at and regularly review current Health Canada advisories, warnings and recalls at: for the most up to date information
Even when diagnosis codes differ, similar conditions can be grouped together based on their clinical relevance
14.3 MOUNJARO Use in Combination with Metformin, Sulfonylureas, and/or SGLT2 Inhibitors in Adult Patients with Type 2 Diabetes Mellitus Add-on to metformin SURPASS-2 (NCT03987919) was a 40-week open-label trial (double-blind with respect to MOUNJARO dose assignment) that randomized 1879 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin alone to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or MOUNJARO 15 mg once weekly or subcutaneous semaglutide 1 mg once weekly
Strengthens immunity: Healthy red blood cell formation and overall wellness support natural immune function
These result from its systemic growth-promoting effects